Molecular Imaging in Focus: New Insights on the Emerging Tau PET Agent Florquinitau F 18 and Early Alzheimer’s Disease
In a recent episode of our Molecular Imaging in Focus series, Christopher Rowe, MD, BMBS, FRACP, FAANMS, discussed pertinent phase 3 study findings for florquinitau F 18 that were presented at the recent Clinical Trials on Alzheimer’s Disease conference.
Could an emerging tau PET radiotracer and a new clinico-imaging reference standard for phase 3 trials of diagnostic agents bolster early detection of Alzheimer’s disease?
Assessing the utility of the
The researchers found that florquinitau F 18 demonstrated sensitivity rates between 79.9 percent to 88.5 percent for one study and 68.2 percent to 82.4 percent for the second study. Across both studies, the authors noted specificity rates for florquinitau F 18 ranging between 93.5 percent to 99.4 percent, an average positive predictive value of 98.9 percent and an average negative predictive value of 85.7.1
Could a New Reference Standard for Phase 3 Trials Have an Impact in Assessing PET Agents for Earlier Detection of Alzheimer’s Disease?
In a recent episode of the Molecular Imaging in Focus series, lead study author Christopher Rowe, MD, BMBS, FRACP, FAANMS, emphasized the FDA’s acceptance of a newclinico-imaging reference standard, which incorporated imaging from those at earlier stages for symptomatic Alzheimer’s disease in the phase 3 trials for florquinitau F 18. As Dr. Rowe described it, those with positive amyloid PET scans and cognitive impairment were classified as having tau pathology whereas those with negative amyloid PET scans and normal cognition were not deemed to have tau pathology.
"This new reading method is designed to pick up tau earlier than the currently approved reading process for tau PET. So there's a two-in-one with this one. We've got a new tau tracer, but the FDA has also accepted a new reading method that's more sensitive for early stages of tau," explained Dr. Rowe, the director of molecular imaging research at Austin Health in Victoria, Australia.
Were Previous Trials of Amyloid and Tau PET Tracers Limited to Those with Advanced Disease?
Previous FDA approvals of amyloid and tau PET tracers required postmortem studies, which typically enrolled about a smaller number of participants and took several years to recruit, according to Dr. Rowe. Accordingly, Dr. Rowe said these studies were limited to focusing on those with advanced disease.
“You ended up with a biased cohort of severely advanced dementia patients versus normal so it wasn't reflective of the true population that you're going to use this test in, which is people with mild cognitive impairment and very mild dementia," noted Dr. Rowe, the director of the Australian Dementia Network.
Could Tau PET Facilitate Proper Patient Selection for Anti-Amyloid Therapies in the Future?
In terms of future research, Dr. Rowe would like to see studies evaluating the role of tau PET in patient selection for anti-amyloid therapies, which can be expensive and require infusions for at least 18 months. He pointed out that there were patients in the recently reported five-year lecanemab open-label extension study that still had tau after amyloid clearance and continued to decline.2
“Before embarking on that journey, it is possible to give the patient a more accurate assessment of their likely benefit if a tau scan is done. I think that's a role of tau imaging that hasn't been widely embraced yet, but I think it is a logical area to go in," posited Dr. Rowe.
References
- Rowe CC, Gauthier S, Ishii K, et al. Detection of tau pathology in patients with early Alzheimer’s disease: florquinitau F18 PET in pivotal phase 3 studies. Presented at the Clinical Trials on Alzheimer’s Disease conference, November 16-19, 2026, Boston. Available at:
www.ctad-alzheimer.com/files/medias/documents/Poster_list_CTAD26_app.pdf .
2. Van Dyck CH, Li D, Kanekiyo M, et al. Long-term outcomes in early Alzheimer’s disease: initial findings through 60 months of Clarity AD open-label extension. Presented at the Clinical Trials on Alzheimer’s Disease conference, November 16-19, 2026, Boston. Available at:
Additional Reference
3. Shuping JL, Matthews DC, Adamczuk K, et al. Development, initial validation and application of a visual read method for (18F)MK-6240 tau PET. Alzheimers Dement (N.Y.). 2023;9(1):e12372. doi: 10.1002/trc2.12372. eCollection 2023 Jan-Mar.
Related to this article








